Source link : https://www.newshealth.biz/health-news/sticking-with-cdk4-6-inhibitors-for-breast-cancer-wins-in-post-progression-setting/
Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors had better survival if they continued CDK4/6 inhibition plus endocrine therapy rather than switch to endocrine therapy alone, a large meta-analysis showed. The hazard for progression-free (PFS) and overall survival (OS) decreased by about 40% when patients continued CDK4/6 inhibition and also […]
Author : News Health
Publish date : 2024-12-20 16:48:43
Copyright for syndicated content belongs to the linked Source.